{ "resourceType": "PlanDefinition", "id": "KDN5", "text": { "status": "additional", "div": "
\n \n \n \n \n \n \n
\n \n
National Comprehensive Cancer Network
\n
\n

Chemotherapy Order Template

\n

Kidney Cancer

\n

Gemcitabine/CARBOplatin

\n
KDN5
\n \n \n \n \n \n \n
\n

INDICATION:

\n

Metastatic or Relapsed – Collecting Duct/Medullary Subtypes

\n
\n

REFERENCES:

\n
    \n
  1. NCCN Guidelines® for Kidney Cancer. V.3.2015.
  2. \n
  3. Oudard S, et al. J Urol. 2007;177(5):1698-702.\n a\n
  4. \n
\n
\n

NCCN SUPPORTIVE CARE:

\n
    \n
  1. \n Emetic Risk:\n \n \n \n \n \n \n \n \n \n
    Day 1Moderate
    Day 8Low
    \n
  2. \n
  3. \n Fever Neutropenia Risk:
    \n Refer to NCCN Guidelines for Myeloid Growth Factors. V.2.2014\n
  4. \n
\n
\n \n

CHEMOTHERAPY REGIMEN

\n

\n 21-day cycle for 6 cycles\n

\n \n
" }, "contained": [ { "resourceType": "ActivityDefinition", "id": "1111", "status": "draft", "productCodeableConcept": { "coding": [ { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "code": "12574", "display": "gemcitabine" } ], "text": "gemcitabine" }, "dosage": [ { "text": "1250 mg/m² IV over 30 minutes", "timing": { "repeat": { "duration": 30, "durationUnit": "min" } }, "route": { "text": "IV" }, "doseQuantity": { "value": 1250, "unit": "mg/m²" } } ] }, { "resourceType": "ActivityDefinition", "id": "2222", "status": "draft", "productCodeableConcept": { "coding": [ { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "code": "40048", "display": "Carboplatin" } ], "text": "CARBOplatin" }, "dosage": [ { "text": "AUC 5 IV over 30 minutes", "timing": { "repeat": { "duration": 30, "durationUnit": "min" } }, "route": { "text": "IV" }, "doseQuantity": { "extension": [ { "url": "http://example.org/fhir/AUC-dose", "valueInteger": 5 } ] } } ] } ], "identifier": [ { "system": "http://example.org/ordertemplates", "value": "KDN5" } ], "version": "1", "title": "Gemcitabine/CARBOplatin", "type": { "text": "Chemotherapy Order Template" }, "status": "draft", "experimental": true, "publisher": "National Comprehensive Cancer Network, Inc.", "approvalDate": "2016-07-27", "lastReviewDate": "2016-07-27", "useContext": [ { "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString": "A" } ], "code": { "system": "http://example.org/fhir/CodeSystem/indications", "code": "treamentSetting-or-diseaseStatus" }, "valueCodeableConcept": { "text": "Metastatic" } }, { "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString": "A" } ], "code": { "system": "http://example.org/fhir/CodeSystem/indications", "code": "disease-or-histology" }, "valueCodeableConcept": { "text": "Collecting Duct/Medullary Subtypes" } }, { "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString": "A" } ], "code": { "system": "http://hl7.org/fhir/usage-context-type", "code": "focus" }, "valueCodeableConcept": { "text": "Kidney Cancer" } }, { "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString": "B" } ], "code": { "system": "http://example.org/fhir/CodeSystem/indications", "code": "treatmentSetting-or-diseaseStatus" }, "valueCodeableConcept": { "text": "Relapsed" } }, { "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString": "B" } ], "code": { "system": "http://example.org/fhir/CodeSystem/indications", "code": "disease-or-histology" }, "valueCodeableConcept": { "text": "Collecting Duct/Medullary Subtypes" } }, { "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString": "B" } ], "code": { "system": "http://hl7.org/fhir/usage-context-type", "code": "focus" }, "valueCodeableConcept": { "text": "Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic" } } ], "contributor": [ { "type": "author", "name": "Lee Surprenant" } ], "copyright": "All rights reserved.", "relatedArtifact": [ { "type": "derived-from", "display": "NCCN Guidelines for Kidney Cancer. V.2.2016", "url": "http://www.example.org/professionals/physician_gls/PDF/kidney.pdf" }, { "type": "citation", "_type": { "extension": [ { "url": "http://example.org/fhir/regimenReferenceType", "valueCode": "a" } ] }, "citation": "Oudard S, et al. J Urol. 2007;177(5):1698-702", "url": "http://www.ncbi.nlm.nih.gov/pubmed/17437788" } ], "action": [ { "selectionBehavior": "exactly-one", "action": [ { "selectionBehavior": "all", "action": [ { "groupingBehavior": "sentence-group", "selectionBehavior": "exactly-one", "action": [ { "id": "cycle-definition-1", "textEquivalent": "21-day cycle for 6 cycles", "timingTiming": { "repeat": { "count": 6, "duration": 21, "durationUnit": "d" } }, "action": [ { "id": "action-1", "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle", "extension": [ { "url": "day", "valueInteger": 1 }, { "url": "day", "valueInteger": 8 } ] } ], "textEquivalent": "Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8", "definition": { "reference": "#1111" } }, { "id": "action-2", "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle", "extension": [ { "url": "day", "valueInteger": 1 } ] } ], "textEquivalent": "CARBOplatin AUC 5 IV over 30 minutes on Day 1", "relatedAction": [ { "actionId": "action-1", "relationship": "concurrent-with-start" } ], "definition": { "reference": "#2222" } } ] } ] } ] } ] } ] }